(Q24242892)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17943842%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

0 references

1 reference

title

Rifabutin for treating pulmonary tuberculosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17943842%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

main subject

tuberculosis

0 references

pulmonary tuberculosis

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17943842%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

G Davies

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17943842%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

L Richeldi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17943842%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

17 October 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17943842%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

9 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17943842%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17943842%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

CD005159

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17943842%20AND%20SRC:MED&resulttype=core&format=json

Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

Criteria for the control of drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

Cochrane Database of Systematic Reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

Use of rifabutin in the treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

Antimicrobial activity of rifabutin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005159.PUB2

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

21 January 2018

1 reference

12 December 2020

Regimens of less than six months for treating tuberculosis

1 reference

12 December 2020

Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis

1 reference

12 December 2020

A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council

1 reference

12 December 2020

[Preliminary results of rifabutine (ansamycine LM 427) treatment of patients with newly detected and chronic pulmonary tuberculosis and Mycobacterium infections].

1 reference

12 December 2020

The Garrod Lecture. Understanding the chemotherapy of tuberculosis--current problems

1 reference

12 December 2020

Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases

1 reference

12 December 2020

Activity of the spiropiperidyl rifamycin LM 427 on rifampicin resistant Mycobacterium tuberculosis

1 reference

12 December 2020

Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis

1 reference

12 December 2020

New rifamycins modified at positions 3 and 4. Synthesis, structure and biological evaluation

1 reference

12 December 2020

Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group

1 reference

12 December 2020

10.1002/14651858.CD005159.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

669090

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17943842%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

669090

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17943842%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

PubMed publication ID

17943842

2 references

Consolidated OpenCitations Corpus – April 2017

669090